Skip to main
KLOW Terminal

Full protein, short fragment: where does the evidence end?

KLOW peptide references

The vascular papers, the repair experiments and the safety work, gathered in one reading list.

Starting with a physical result

The BPC-157 vessel-response paper gives the circulation discussion its starting point. The rat tendon experiment and rat wound study with full thymosin beta-4 ask different questions about repair. I favor these concrete measurements when broad claims about KLOW peptide start to sound interchangeable.

Cell work, topical studies and safety

The GHK skin review covers topical and cellular research; the KPV paper includes cell experiments and mouse colitis. The two-adult BPC-157 pilot concerns a brief safety observation. The Sports Medicine review places the larger human evidence gap in context.

Two entries below point to the same BPC-157 vessel paper; they represent one source. Some entries are reviews, so their summaries lead back to earlier experiments.

  1. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
  2. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
  3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3). ↗
  4. Jo JO, et al. Thymosin β4 induces the expression of vascular endothelial growth factor (VEGF) in a hypoxia-inducible factor (HIF)-1α-dependent manner. Biochim Biophys Acta. 2010. ↗
  5. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. ↗
  6. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. ↗
  7. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. ↗
  8. Author group. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025. ↗
  9. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21:976-983. ↗
  10. World Anti-Doping Agency. 2024 Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. WADA. ↗
  11. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  12. Smart N, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007. ↗
  13. Grant DS, et al. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. 2007. ↗
  14. Sosne G, et al. Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4. Front Immunol. 2024. ↗
  15. Wang L, et al. Thymosin β4 improves the survival of cutaneous flaps of rat and activates Wnt/β-catenin signaling. Arch Med Sci. 2024. ↗
  16. Sever'yanova LA, Dolgintsev ME. Effects of Tripeptide Gly-His-Lys in Pain-Induced Aggressive-Defensive Behavior in Rats. Bulletin of Experimental Biology and Medicine. 2017;164(2):140-143. ↗
  17. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. ↗